Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
IMAX ( (IMAX) ) has provided an update.
Auxly Cannabis Group Inc. reported a strong financial performance for the first quarter of 2025, with a 29% increase in net revenues to $32.7 million and a 232% rise in adjusted EBITDA. The company maintained its position as a top player in the Canadian cannabis market, with its Back Forty brand achieving the number one spot in Canada. Auxly’s strategic focus on innovation and operational efficiency has resulted in significant growth, reinforcing its market leadership and setting a solid foundation for future expansion.
The most recent analyst rating on (IMAX) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on IMAX stock, see the IMAX Stock Forecast page.
Spark’s Take on IMAX Stock
According to Spark, TipRanks’ AI Analyst, IMAX is a Outperform.
IMAX’s overall score is driven by its strong financial performance and positive earnings outlook, despite high valuation and mixed technical signals. The company’s robust cash flow and profitability, along with strategic expansion and leadership appointments, support a favorable long-term view. However, the high P/E ratio and absence of dividend yield temper short-term enthusiasm.
To see Spark’s full report on IMAX stock, click here.
More about IMAX
Auxly Cannabis Group Inc. is a leading consumer packaged goods company in the cannabis products market. The company focuses on producing and distributing cannabis products and holds a significant market share in Canada, ranking as the fourth largest licensed producer.
Average Trading Volume: 1,034,156
Technical Sentiment Signal: Buy
Current Market Cap: $1.41B
For an in-depth examination of IMAX stock, go to TipRanks’ Stock Analysis page.